DMAAR

Drugs Made In America Acquisition Corp Rights
DMAAR

Overview Fund Trends Analyst Outlook Journalist POV

19 hedge funds and large institutions have $2.53M invested in Drugs Made In America Acquisition Corp Rights in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
19
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$807K
2
+$247K
3
+$234K
4
HCI
Harraden Circle Investments
New York
+$195K
5
GCL
Glazer Capital LLC
New York
+$169K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
1
Crossingbridge Advisors
New York
$807K
PAMP
2
Polar Asset Management Partners
Ontario, Canada
$247K
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
$234K
HCI
4
Harraden Circle Investments
New York
$195K
GCL
5
Glazer Capital LLC
New York
$169K
AC
6
Aristeia Capital
Connecticut
$117K
MP
7
Mangrove Partners
Connecticut
$111K
HCM
8
Highbridge Capital Management
New York
$111K
WAM
9
Wolverine Asset Management
Illinois
$78.4K
ASM
10
ATW SPAC Management
New York
$74.1K
CS
11
Clear Street
New York
$71.5K
AA
12
AQR Arbitrage
Connecticut
$65K
CF
13
Cantor Fitzgerald
New York
$65K
LP
14
LMR Partners
United Kingdom
$65K
WA
15
Whitebox Advisors
Minnesota
$52K
SSA
16
Schonfeld Strategic Advisors
New York
$26K
MSU
17
Mizuho Securities USA
New York
$21K
QL
18
Quarry LP
New York
$19.5K
WAM
19
Warberg Asset Management
Illinois
$2.4K